A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas

Advanced Solid Tumors or Lymphomas Clinical Trial

Official title:

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Recombinant Fully Human Anti-CD39 Monoclonal Antibody JS019 in Patients With Advanced Solid Tumors or Lymphomas

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05374226
• Other study ID #: JS019-001-I
• Status: Recruiting
• Phase: Phase 1
• Start date: March 31, 2022
• Est. completion date: March 7, 2024

Study information

• Verified date: April 2022
• Source: Suzhou Kebo Ruijun Biotechnology Co., Ltd
• Contact: lin shen, Doctor of medicine
• Phone: 8610-88196561
• Email: linshenpku[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JS019 as monotherapy in patients with advanced malignant solid tumors/lymphomas.

The study includes JS019 monotherapy dose escalation, dose expansion and indication expansion stages to investigate the safety, tolerability, pharmacokinetics and preliminary anti-tumor efficacy of JS019 as monotherapy.

Description:

Monotherapy Dose Escalation Stage:

In this stage, the safety and tolerability, PK characteristics, immunogenicity and PD of JS019 are investigated. Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration. During the study, necessary adjustments may be made to the escalating dose and dosing interval based on the safety, PK and other results obtained.

Monotherapy Dose Expansion Stage:

SMC will select 1~2 dose levels (dose levels in the monotherapy dose escalation stage or intermediate dose levels) of JS019 as monotherapy. Each dose level includes 6~9 subjects with advanced malignancies to further evaluate the safety, pharmacokinetics, immunogenicity, pharmacodynamics and efficacy of JS019 as monotherapy, and determine the RP2D of JS019 as monotherapy.

Monotherapy Indication Expansion Stage Based on the determined RP2D of JS019 as monotherapy, 2-4 specific malignancies are selected for indication expansion; about 20-30 patients are included for each indication. It is planned to include expansion cohorts to explore the efficacy and safety of JS019 as monotherapy. The actual cohorts included may be adjusted based on the results of the previous studies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 172
• Est. completion date: March 7, 2024
• Est. primary completion date: December 11, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Be able to understand and willing to sign the Informed Consent Form;

2. Male or female aged 18~75 years (included);

3. Patients with pathologically confirmed advanced malignant solid tumors or lymphomas;

4. Failed or unsuitable for standard treatment, received at least one line of systemic treatment;

5. Eastern Cooperative Oncology Group (ECOG) physical fitness score: 0~1;

6. Expected survival period = 12 weeks;

7. At least one measurable lesion according to criteria RECIST v1.1 or Lugano 2014;

Exclusion Criteria:

1. Patients with known hypersensitivity to the components of JS019;

2. Patients who have received the treatment with anti-CD39 antibodies or inhibitors;

3. Patients who participated in other clinical studies within 4 weeks prior to the first administration of JS019, except patients are in the follow-up period of observational (non-interventional) clinical study or interventional study;

4. Patients who have received major surgery within 4 weeks before the first dose or expected to undergo major surgery during the study (as judged by the investigator) or are in the recovery period from surgery;

5. Patients who have received anti-tumor therapy, such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, or biological therapy, within 4 weeks or 5 half-lives of the therapy (whichever is shorter) prior to the first dose of JS019. Patients who have received traditional Chinese medicine or Chinese patent medicine preparations with anti-tumor indications within 2 weeks before the first dose of JS019. Can accept hormone therapy for non-tumor-related diseases (such as insulin therapy for diabetes and hormone replacement therapy, etc.);

6. Patients who have discontinued immunotherapy due to immune-related AEs.

7. Patients who have used immunosuppressive drugs within 4 weeks prior to the first dose of JS019, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids =10 mg/day prednisone or equivalent.

Related Conditions & MeSH terms

• Advanced Solid Tumors or Lymphomas
• Lymphoma

Intervention

Biological:
• JS019
Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Suzhou Kebo Ruijun Biotechnology Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Biomarkers	The expression levels of CD39, P2X7, PD-L1 and CD8+ in tumor tissue, and the correlation between their expression levels and efficacy.	2 years
Primary	Safety and tolerability	Incidence of DLT, incidence and severity of adverse events (AEs) and serious adverse events (SAEs), clinically significant abnormal changes in laboratory tests and other tests	2 years
Primary	Maximum tolerated dose (MTD, if possible) and the recommended phase 2 dose (RP2D)	Maximum tolerated dose (MTD) : The highest dose at which <1/3 patients experience DLT events.; Phase II recommended dose: safety, pharmacokinetics, and preliminary efficacy data of dose escalation will be integrated. When the Maximum tolerated dose(MTD) is determined, the Maximum tolerated dose(MTD) is usually used as the Phase II recommended dose(RP2D), or the dose lower than the Maximum tolerated dose(MTD) is selected as the Phase II recommended dose(RP2D) based on the comprehensive data.	2 years
Secondary	Pharmacokinetics (PK)	Drug concentrations in individual subjects at different time points after administration	2 years
Secondary	Immunogenicity	Incidence of anti-drug antibodies (ADA), titer of ADA-positive samples.	2 years
Secondary	Pharmacodynamics (PD)	CD39 receptor occupancy in peripheral blood.	2 years
Secondary	Objective response rate (ORR)	The percentage of cases with remission (PR + CR) after treatment was assessable	2 years
Secondary	Duration of response (DOR)	The time from the first assessment of CR or PR to the first assessment of PD or death due to any cause.	2 years
Secondary	Disease control rate (DCR)	The percentage of cases with remission (PR + CR) and stable lesions (SD) after treatment was assessable.	2 years
Secondary	Time to response (TTR)	time from the start of treatment to progression of diease.	2 years
Secondary	Progression-free survival (PFS)	PFS is defined as time from the start of treatment to progression of disease or death.	2 years
Secondary	Overall survival (OS)	Overall survival is defined as time from the start of treatment until death due to any reason.	2 years